Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
[Paper-level Aggregated] PMCID: PMC7302243
Evidence Type(s): Oncogenic
Summary: Mutation: T790M | Summary: The T790M mutation contributes to tumor progression by conferring resistance to targeted therapies in the context of EGFR-driven cancer, indicating its role in treatment response.
Gene→Variant (gene-first): EGFR(1956):T790M
Genes: EGFR(1956)
Variants: T790M
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
[Paper-level Aggregated] PMCID: PMC7302243
Evidence Type(s): Predictive
Summary: Mutation: T790M | Summary: The T790M mutation is associated with acquired resistance to EGFR-TKI therapy in PC9/GR cells, indicating its role in treatment response.
Gene→Variant (gene-first): EGFR(1956):T790M
Genes: EGFR(1956)
Variants: T790M
We examined Mig-6 expression in PC9 cells harboring the EGFR exon 19 deletion and PC9/GR cells, which have EGFR-TKI resistance with an acquired T790M mutation. Western blotting and immunofluorescence analyses showed that
[Paragraph-level] PMCID: PMC7302243 Section: RESULTS PassageIndex: 3
Evidence Type(s): Predictive, Oncogenic
Summary: Evidence Type: Predictive | Mutation: T790M | Summary: The T790M mutation is associated with acquired resistance to EGFR-TKI therapy in PC9/GR cells, indicating its role in treatment response. Evidence Type: Oncogenic | Mutation: T790M | Summary: The T790M mutation contributes to tumor progression by conferring resistance to targeted therapies in the context of EGFR-driven cancer.
Gene→Variant (gene-first): 1956:T790M
Genes: 1956
Variants: T790M
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
[Paper-level Aggregated] PMCID: PMC7302243
Evidence Type(s): Oncogenic, Functional
Justification: Oncogenic: The presence of the T790M mutation in PC9/GR cells is associated with acquired resistance to EGFR-TKI, indicating its role in promoting cancer cell survival and proliferation despite treatment. Functional: The study demonstrates changes in protein expression and phosphorylation status in cells with the T790M mutation, suggesting that this variant affects cellular signaling pathways and functions related to tumor progression.
Gene→Variant (gene-first): EGFR(1956):T790M
Genes: EGFR(1956)
Variants: T790M
We examined Mig-6 expression in PC9 cells harboring the EGFR exon 19 deletion and PC9/GR cells, which have EGFR-TKI resistance with an acquired T790M mutation. Western blotting and immunofluorescence analyses showed that
[Paragraph-level] PMCID: PMC7302243 Section: RESULTS PassageIndex: 3
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The passage discusses the acquired T790M mutation in the context of EGFR-TKI resistance, indicating a correlation with treatment resistance. Oncogenic: The T790M mutation is described as contributing to EGFR-TKI resistance, which is a characteristic of tumor progression in the context of cancer.
Gene→Variant (gene-first): 1956:T790M
Genes: 1956
Variants: T790M
We examined Mig-6 expression in PC9 cells harboring the EGFR exon 19 deletion and PC9/GR cells, which have EGFR-TKI resistance with an acquired T790M mutation. Western blotting and immunofluorescence analyses showed that
[Paragraph-level] PMCID: PMC7302243 Section: RESULTS PassageIndex: 3
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The passage discusses the acquired T790M mutation in the context of EGFR-TKI resistance, indicating a correlation with treatment resistance. Oncogenic: The T790M mutation is described as contributing to EGFR-TKI resistance, which is a characteristic of tumor progression in the context of cancer.
Gene→Variant (gene-first): 1956:T790M
Genes: 1956
Variants: T790M